Skip to main content
Ipsen Home Page
Press shift tab to select search category
Loading...
  • Newsroom
  • Investors
  • Careers arrow down
      < Back
    • Careers
    • Careers
    • Working at Ipsen
    • Our Culture
  • Press shift tab to select search category
    Loading...
  •  Singapore
    < Back
    • Global EN FR
    • Annual Report EN FR
    • Americas
    • Asia Pacific
    • Europe
    • Middle East & Africa
    • United States
    • Brazil
    • Canada
    • Mexico
    • Australia
    • China
    • Singapore
    • South Korea
    • Japan
    • Belgium
    • Ukraine
    • UK
    • Germany
    • France
    • Nordics
    • Greece
    • Italy
    • Netherlands
    • Spain
    • Poland
    • Russia
    • Czech Republic
    • Switzerland
    • Austria
    • UAE & Gulf
  • Home
  • Company
      < Back
    • Company
    • Company
    • History
  • Expertise
      < Back
    • Expertise
    • Oncology
    • Rare Disease
    • Neuroscience
  • Science
      < Back
    • Science
    • Pipeline
    • Clinical Trials
        < Back
      • Clinical Trials
      • Find Clinical Trials
    • Products
        < Back
      • Products
      • Cabometyx® (cabozantinib)
      • Diphereline® (triptorelin pamoate or acetate)
      • Dysport® (abobotulinumtoxinA)
      • Iqirvo® (elafibranor)
      • Somatuline® Autogel® (lanreotide acetate)

Post navigation

Previous
Next

Diphereline® (triptorelin pamoate or acetate)

Diphereline® (triptorelin pamoate or acetate)

- 31 October 2025 - 0 mins read

Post navigation

Previous
Next
Related Documents
  • Diphereline PR 3.75mg Package Insert   Download  (492 KB)
  • Diphereline PR 11.25mg Package Insert   Download  (425 KB)

Related Products

Iqirvo® (elafibranor)
31 October 2025 0 mins read

Iqirvo® (elafibranor)
Somatuline® Autogel® (lanreotide acetate)
31 October 2025 0 mins read

Somatuline® Autogel® (lanreotide acetate)
Dysport® (abobotulinumtoxinA)
31 October 2025 0 mins read

Dysport® (abobotulinumtoxinA)
Cabometyx® (cabozantinib)
31 October 2025 0 mins read

Cabometyx® (cabozantinib)

IPN price

€160.90

 €-3.70 (-2.25%)

Ipsen logo
LinkedIn Instagram Facebook Youtube
  • Terms & Conditions
  • Cookie Policy
  • Privacy Policy

© Ipsen Pharma. All rights reserved - 2026. CRSC-SG-000012

You are now leaving the Ipsen group website. To continue, please click on Continue?

Continue